Clinical trial
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
NCT06873100 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- November 15, 2024
- Completion date
- December 31, 2026
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing polychondritis